To include your compound in the COVID-19 Resource Center, submit it here.

EntreMed, Oxford BioMedica deal

ENMD granted OXB exclusive global rights to its angiostatin and endostatin

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE